Jiajian Medical Secures RMB 200 Million Series B+ Financing Led by CICC Capital to Advance China's Birth Defect Prevention System

VCBeat has learned that Guangzhou Jiajian Medical Testing Co., Ltd. (“Jiajian Medical”) recently announced the completion of its Series B+ financing round, raising nearly RMB 200 million.Led by CICC Qide Fund, under CICC Capital, with follow-on investments from institutions such as Besen Medical Fund, TECHNOLOGY FINANCIAL GROUP, and Jointown Venture Capital.

Data shows that Guangzhou Jiajian Medical Testing Co., Ltd. was established in August 2015 on Guangzhou Bio Island. Its mission is to provide specialized clinical genetics services, offering comprehensive solutions for professional clinical genetic disease diagnosis and genetic counseling. It is an integrated biomedical enterprise combining clinical laboratory services with the development and production of in vitro diagnostic (IVD) kits. With the goal of reducing the birth defect rate by 1%, the company envisions building “domestically produced, localized, and specialized” clinical genetics specialties and is committed to promoting the translational application of genomic testing technologies in clinical practice.

In light of the new trends in national medical regulation in the post-pandemic era, an increasing number of healthcare institutions are favoring this collaborative model, which is more conducive to building local clinical genetics systems. Guangzhou Jiajian Medical Testing Co., Ltd. has actively responded to the policy promoting the substitution of imported products with domestically produced ones. By leveraging its genetic disease testing platform based on AmCare-Seq 2000, a domestically manufactured gene sequencer specifically designed for genetic disease detection, the company enables hospitals to conduct clinical genetic testing and screening for genetic disorders in-house. This facilitates precision treatment and provides guidance for subsequent pregnancies, thereby establishing a series of safeguard measures for future assisted reproductive technologies.

Guangzhou Jiajian Medical Testing Co., Ltd. is committed to leveraging continuously optimized genomic testing products as a tool to comprehensively and rapidly assess genetic and variant factors contributing to birth defects, thereby creating a one-stop solution closely aligned with clinical practice. The company provides healthcare institutions at all levels with professional and clinically appropriate molecular diagnostic instruments, reagents, and software, while also offering services such as clinical staff training, hospital-based consultations, and personalized genetic counseling. Due to its robust technological capabilities in product development and impressive performance growth, Jiajian Medical has long been favored by investors across the board. The funds from this round of financing will be primarily allocated to the research, development, and registration of its diagnostic reagent pipeline, further perfecting the upstream and downstream closed-loop system within the genomic disease diagnosis industry, and simultaneously driving industrial upgrading toward a comprehensive “diagnosis, screening, prevention, and treatment” closed loop for genomic diseases.

Under the guidance of the national "Healthy China" initiative, Guangzhou Jiajian Medical Testing Co., Ltd. is collaborating with domestic and international experts in clinical genetics, as well as early- and mid-career clinical geneticists, to become a preferred partner for the prevention and control of birth defects. Meanwhile, driven by technological innovation and other factors, the company has been recognized as a “National High-Tech Enterprise,” a “Gazelle Enterprise” in the Huangpu District Development Zone of Guangzhou, a “Guangzhou Unicorn,” and one of the “Top 50 Enterprises in the Guangdong-Hong Kong-Macao Greater Bay Area.”

In recent years, with the rapid advancement of key biotechnologies such as genomics, stem cell research, and CRISPR, our understanding of the etiology of human diseases and effective therapeutic strategies has progressed significantly. Across clinical disciplines, physicians’ approaches to disease recognition and treatment are gradually shifting from being driven by clinical phenotypes or imaging findings to being driven by genotypes. The new era of healthcare is marked by the milestone of molecular diagnosis and screening.

Dr. Zhang Wei, Founder and CEO of Jiajian MedicalIt stated: “As our understanding of the profound impact of genetic diseases on families and society deepens, and particularly with the large-scale clinical application of genomic testing technologies in the prevention and control of birth defects, it is essential to further promote the adoption of genomic testing products in hospitals at all levels. This will help advance the specialty of clinical genetics, ensure the quality of genomic products, effectively improve population health, and reduce the medical burden on society and families. Guangzhou Jiajian Medical Testing Co., Ltd. is committed to becoming the preferred partner for birth defect prevention and control. The company will continue to uphold its mission and vision, drive the development of clinical genetics, implement high-quality services and products related to birth defect prevention and control, and work collaboratively with all stakeholders to reduce the incidence of birth defects.”

CICC QideFund Manager: Liang YingMs.It stated: “A nation’s long-term economic development is closely tied to its population size. As China’s total population growth has reached an inflection point, the government has placed particular emphasis in recent years on fertility rates, the improvement of population quality, and the prevention and control of birth defects arising therefrom. Jiajian Medical is a leading specialized enterprise strategically positioned by CICC Qide in the niche segment of tertiary prevention of birth defects. The upgrade of clinical diagnosis and treatment pathways driven by genomic technology has become an inevitable trend in clinical medicine. Jiajian Medical is a rare IVD company in the industry that focuses on clinical diagnosis, screening, and genetic counseling for hereditary diseases. It has established a complete industrial closed loop through continuous optimization of underlying technologies—including software, hardware, general-purpose testing reagents, and the R&D, registration, production, and effective commercialization of Class III diagnostic reagents. Looking ahead, under the leadership of its founder, Dr. Zhang Wei, Jiajian Medical aims to achieve rapid growth, build core corporate competitiveness, further strengthen the implementation of localized solutions for hospitals based on clinical genetics specialization, and truly become the preferred partner for healthcare organizations at all levels.”

Partner at Besen Medical FundLiu YingMs.“It is stated that there are over 7,000 confirmed monogenic inherited diseases worldwide, with approximately 900,000 new cases of birth defects occurring annually in China. The national emphasis on genetic rare diseases has been increasing year by year. The deepening clinical application of genomic testing technology can address the diagnostic challenges of genetic rare diseases; however, given the complex clinical manifestations of genetic disorders, genomic testing technologies must be closely integrated with clinical medicine. The team led by Dr. Zhang Wei at Jiajian Medical represents the only enterprise in China with dual clinical certifications from ABMG. Over the past seven years, the company has established a comprehensive product system encompassing genetic testing equipment, high-precision gene panels, reagents, and custom probes, and has built a database of tens of thousands of cases documenting genetic mutations specific to the Chinese population. As the first genetic testing project invested in by Besen Medical Fund, we are highly optimistic about Jiajian’s future.”

Head of the Biomedical Group, Guangdong Yueke Venture Capital Management Co., Ltd.Mr. Li YanStatement: Jiajian Medical is a leading enterprise focused on genetic diagnosis, screening, and counseling for hereditary diseases. The company boasts an industry-leading team background, academic influence, and brand reputation, along with strong capabilities in product line development and industrial translation. It is also one of the few players in this sector that has completed upstream supply chain layout. While genetic diagnosis and counseling for hereditary diseases offer clear clinical value, their penetration rate remains low in China. Precision medicine, early diagnosis and treatment, and eugenics are long-term strategic directions guided by national policies. Against this backdrop, we believe that Jiajian Medical’s products—such as Clinical Exome Plus, full-length mitochondrial genome sequencing, and rapid dual-genome testing for hereditary diseases—can accelerate market penetration, providing broader families and patient populations with more precise, convenient, and cost-effective high-quality counseling, screening, and diagnostic services for hereditary diseases.

Mr. Wang Yongfei, Assistant to the General Manager of Jointown Venture Capital and Director of the Cell and Gene IndustryStatement: Eugenics and healthy childbirth are fundamental national policies in China, with genetic disease testing technologies serving as crucial tools for their implementation, holding significant social importance. Guangzhou Jiajian Medical Testing Co., Ltd. possesses core competencies in “genetic testing + bioinformatics analysis + medical interpretation,” featuring industry-leading high-precision clinical exome sequencing and mitochondrial testing technologies. Positioned in the first tier within the rapidly expanding genetic disease testing market, the company holds promising future prospects. We are highly committed to supporting its continued growth.

According to data published by the World Health Organization, there are approximately 7,000 confirmed monogenic genetic diseases worldwide. Although the incidence rate of any single genetic disorder is low, the overall prevalence remains high due to the vast number of disease types. Statistical data from China’s former Ministry of Health in 2012 indicated a birth defect rate of 5.6%, with preventable and controllable genetic disorders accounting for approximately one-quarter of these cases. Except for a small subset that can be corrected through medical interventions, most monogenic genetic diseases carry risks of mortality, disability, or congenital malformations, and lack effective treatment options. Recent estimates suggest that the lifetime familial and socioeconomic burden for raising a child with a genetic disorder amounts to nearly RMB 4 million.

With the rapid advancement of key biotechnologies such as genomics, stem cells, and CRISPR, our understanding of the etiology of human diseases and the development of effective therapeutic strategies have progressed significantly. Currently, there is a substantial clinical demand for the development of precise genetic testing and diagnosis of genetic disorders. Particularly in the context of China’s relaxed population policies, screening and diagnosis of genetic diseases are especially necessary, as they can effectively reduce birth defects and alleviate the burden on families and society.

Dr. Wei ZhangIt stated: “Since its inception, Guangzhou Jiajian Medical Testing Co., Ltd. has adhered to the use of self-designed software and domestically produced hardware. Through seven years of accumulation and consolidation, the company has completed the research, development, and validation of an automated and intelligent system for the entire sample workflow. This has enabled the deployment of its proprietary intelligent analysis system in key stages of genetic testing and analysis, thereby promoting the ‘domestic production, localization, and specialization’ of the genome-related bioeconomy.”

CICC Capital Management Co., Ltd. (“CICC Capital”), a wholly-owned private investment management subsidiary of China International Capital Corporation Limited (“CICC”), serves as CICC’s platform for private investment fund business, centrally managing its domestic and overseas private investment fund operations. As of the end of 2021, CICC Capital had cumulative assets under management exceeding RMB 400 billion, supported by a professional investment management team of over 400 members, establishing it as a leading private equity fund management institution in China.

CICC Qide Fund is an equity investment fund under CICC Capital that focuses on innovative pharmaceuticals, representing a major breakthrough in CICC Capital’s strategic layout within the biopharmaceutical industry. Leveraging its strong performance record, reputable brand, and superior investment management capabilities, CICC Qide Fund has earned recognition and support from numerous well-known fund-of-funds, institutional investors, listed companies, and clients of CICC Wealth Management.

Beisen Medical Fund was established in 2017 and is managed by the professional team of Zhongtong Rongjin. It focuses on investing in advanced technologies in the fields of original drugs, cell therapy, high-end medical devices, and precision medicine. Guided by its core philosophy of investing in advanced technologies, independent innovation, and addressing gaps in clinical applications, the fund allocates 70% of its investments to Series A–B stages. Leveraging the investment team’s extensive industry resources and operational expertise, it provides post-investment services to portfolio companies, fostering technological innovation and industrial upgrading in China’s healthcare sector. Portfolio companies include Zhuokai Biotechnology, Xunuo Pharmaceutical, Runxin Biotechnology, Daying Technology, Hanmei Technology, Yida Biotechnology, and Mingfeng Medical, among others.

Guangdong Technology Financial Group is a state-owned enterprise authorized for operation by the People's Government of Guangdong Province. It is one of the earliest venture capital institutions established in China, the first provincial-level technology finance group in the country, and the only provincial comprehensive technology finance platform in Guangdong Province. Since its inception, the Group has been committed to providing comprehensive financial services for technological innovation in Guangdong. Guangdong Technology Financial Group strives to become a mainstay in sci-tech innovation investment, a driver of strategic emerging industries, and a discoverer and creator of value through the integration of technology and finance, playing a significant role in building Guangdong into a province strong in science and technology and finance, as well as in promoting high-quality development. As of December 2021, the Group independently managed or held equity stakes in 109 funds, with a total fund size of RMB 46.45 billion. The Group has cumulatively provided investment and financing services to more than 2,000 technology enterprises, facilitating the IPO listings of over 80 companies.

Jointown Smart Healthcare Equity Investment Fund is an equity investment fund initiated and established by Jointown Pharmaceutical Group Co., Ltd., primarily targeting the broader health sector. Rooted in industries such as pharmaceutical distribution, logistics services, and medical healthcare, the Group’s core businesses encompass five major areas: pharmaceutical distribution and supply chain services, general agency and sales alongside industrial self-production, digital retail, digital logistics and supply chain solutions, and value-added services in medical health and technology. By continuously optimizing its management structure and actively exploring new development models, the Group has achieved comprehensive omni-channel and full-category business layout and expansion, yielding substantial results in transforming traditional operations into a new model characterized by platformization, internet integration, and digitalization. Committed to building a sustainable growth ecosystem for its portfolio companies, Jointown Smart Healthcare Fund leverages the extensive resources of Jointown Group, which boasts an annual output value exceeding RMB 100 billion, to provide value-added services and maximize the development potential of its investee enterprises.